Lince Capital logo
Venture CapitalFully subscribed

Lince Innovation Fund II

Fully subscribed Lince Capital fund financing R&D-driven Portuguese companies in tech and healthcare; ~€69.7M raised across two subfunds.

Managed by Lince Capital · Av. Eng.º Duarte Pacheco, Torre 2, Piso 17, 1070-102 Lisbon, Portugal

Key facts

€100k
Minimum investment
—
Management fee p.a.
—
Lock-up
—
Target return
Fund status
Fully subscribed
Redemption
~At end of term2
NAV frequency
—
Performance fee
—
Hurdle rate
—
Subscription fee
—
Redemption fee
—
Fund size
~€69.7M2
Target size
—
Inception
—
Fund term
8 years1
Distribution
—
CMVM ID
—
ISIN
—
Legal structure
Closed-end fund with two subfunds (Subfund I and Subfund II), per the manager's funds page2
Domicile
Portugal2
Custodian
—
Auditor
—

For US investors

US investors accepted
—
PFIC status
—
Annual QEF statements
—
IRA / 401(k) route
—

No public information on US investor acceptance. As a non-US pooled fund it would be expected to be a PFIC for US taxpayers; no QEF information published. The fund is closed to new subscriptions, so this is largely moot for new investors.

Fees & costs

—
Management fee p.a.
—
Performance fee
—
Hurdle rate
—
Subscription fee
—
Redemption fee

Performance

No audited performance data is publicly available for this fund yet. We only show returns we can trace to fund reporting — never marketing projections presented as track record.

Documents

  • Lince Capital — Investment Funds (Innovation Fund II Subfund I & II cards)

    Manager website · EN · accessed Jul 7, 2026

    Open

Data transparency

Researched Jul 7, 2026 · every fact carries its source

31%
data completeness

Still researching

  • Management fee
  • Performance fee
  • Lock-up period
  • CMVM registration
  • US investor acceptance
  • ISIN
  • Target fund size
  • Inception date
  • NAV frequency
  • Hurdle rate
  • Subscription fee
  • Redemption fee
  • Custodian
  • Auditor
  • Target return
  • Distribution policy
  • PFIC status
  • QEF reporting
  • IRA/401(k) eligibility
  • Portfolio allocation

Sources

  1. 1Lince Innovation Fund II — Nomad Gate profile — Nomad Gate (aggregator), accessed Jul 7, 2026
  2. 2Lince Capital investment funds overview (subscribed capital per subfund) — Lince Capital (manager), accessed Jul 7, 2026

Research summary

Compiled from the sources cited on this page — a factual summary, not a recommendation or rating.

Lince Innovation Fund II was Lince Capital's Golden Visa-oriented R&D vehicle, financing Portuguese companies focused on innovation and research & development in the technology and healthcare sectors. It sits between Innovation Fund I (€36M, health/tech/industrial) and the much larger Innovation Fund III (€146M) in the Lisbon manager's fund lineage. The fund was structured in two subfunds, which Lince's site shows as fully subscribed with €64.6M (Subfund I) and €5.1M (Subfund II) of capital — roughly €69.7M combined.

Subscriptions ended in August 2024 per Nomad Gate, whose profile records a €100,000 minimum ticket and an 8-year duration; a fund representative had confirmed continued Golden Visa eligibility under the post-October 2023 rules, credible given the non-real-estate R&D mandate (unlike several of Lince's property-flavoured funds). No fee schedule, ISIN, CMVM number or performance data is public. The profile is retained for reference; investors interested in the strategy today would look at Lince's open successor funds.

Suited for

  • ·Reference only — both subfunds are fully subscribed (subscriptions ended August 2024)
  • ·Useful as background on Lince Capital's Innovation fund series when evaluating its currently open funds

Risk factors

  • ·Closed-end ~8-year structure — capital locked until term with no published interim liquidity
  • ·Venture/R&D financing risk concentrated in Portuguese tech and healthcare companies
  • ·Minimal public disclosure: no fees, ISIN, CMVM number or performance data published

Listed for completeness, drawn from fund materials and public sources — not an assessment. How much weight any factor deserves depends on your own situation and risk appetite.

Tom Brooks

Tom Brooks

Founding Partner & CEO

Talk through Lince Innovation Fund II and how it fits your Golden Visa plan — independent guidance, no obligation.

Book a free consultationor email hello@rootsglobal.com